President’s Message – Summer NETNEWS
It is my pleasure to once again share a quick note on the work of CNETS Canada over the past several months. As always, we have been incredibly busy [...]
AWARENESS COMMITTEE / COMITÉ SENSIBILISATION
CNETS Canada is looking for volunteers to join our NET Cancer Awareness Committee. Specific knowledge of NETs or charitable experience is not required but will be considered an asset. [...]
68Ga-DOTATATE PET scan in Ontario
68Ga-DOTATATE PET scan in Ontario Cancer Care Ontario has announced that as of April 1st, 2019, Ontario patients with neuroendocrine tumours (NETs) meeting eligibility criteria are able to have [...]
CNETS Canada Board of Directors Announcement
As we start 2019 we bid farewell to a long-time board member and welcome three new board members to CNETS Canada’s Board of Directors. We extend our heartfelt gratitude to [...]
Jackie Herman Elected To The Board of INCA
Our very own Jackie Herman, CNETS Canada President was elected to the International Neuroendocrine Cancer Alliance (INCA) on January 30th, 2019. INCA welcomed 2 new Directors to the INCA [...]
Toronto’s CN Tower Lights Up Black & White!
November 10, 2018 - Toronto's CN Tower lights up black & white in honour of NET Cancer Awareness Day
Health Canada approves XERMELO™ (telotristat ethyl)
Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase [...]
ePatient Magazine – Focus on NETs
The latest edition of the ePatient magazine has several articles that focus on Neuroendcorine Tumours (NETs). Check it out at: ePatient Magazine
Public Listings for Caprelsa
Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the [...]
Patient Input – Treatment with Telotristat
TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat [...]